{"id":"switch-from-tenofovir-to-abacavir","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Abacavir is a prodrug that is converted into its active form, carbovir, which then inhibits the reverse transcriptase enzyme, a crucial component of the HIV replication cycle. This inhibition prevents the virus from replicating and reduces the viral load in the body.","oneSentence":"Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that works by inhibiting the replication of HIV.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:05.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in combination with other antiretroviral agents"}]},"trialDetails":[{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT04340388","phase":"PHASE4","title":"Contribution of Dolutegravir to Obesity and Cardiovascular Disease","status":"COMPLETED","sponsor":"Augusta University","startDate":"2020-09-17","conditions":"HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases","enrollment":10},{"nctId":"NCT04301661","phase":"","title":"Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-03-06","conditions":"HIV-1-infection","enrollment":25},{"nctId":"NCT03685500","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2018-12-04","conditions":"HIV Infections","enrollment":78},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03067285","phase":"PHASE4","title":"A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2017-09-08","conditions":"HIV Infections","enrollment":39},{"nctId":"NCT04155554","phase":"PHASE3","title":"Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Senese","startDate":"2020-01-29","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT02957864","phase":"PHASE4","title":"Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2016-10","conditions":"Renal Insufficiency,Chronic, Hiv, Therapeutic Agent Toxicity","enrollment":80},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT00958100","phase":"PHASE2","title":"Raltegravir Switch for Toxicity or Adverse Events","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2009-08","conditions":"HIV/AIDS, Antiretroviral Therapy, HIV Infections","enrollment":40},{"nctId":"NCT00960622","phase":"PHASE4","title":"Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects","status":"COMPLETED","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2006-08","conditions":"HIV","enrollment":17},{"nctId":"NCT01153217","phase":"PHASE3","title":"Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral Density","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2010-07","conditions":"HIV","enrollment":54},{"nctId":"NCT00998582","phase":"PHASE4","title":"Artery Elasticity After Switch From Epzicom to Truvada","status":"TERMINATED","sponsor":"Hennepin Healthcare Research Institute","startDate":"2009-10","conditions":"HIV Infections","enrollment":27},{"nctId":"NCT00615810","phase":"PHASE4","title":"ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-03","conditions":"HIV Infections","enrollment":159}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":173,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Abacavir"],"phase":"phase_3","status":"active","brandName":"Switch from tenofovir to abacavir","genericName":"Switch from tenofovir to abacavir","companyName":"Germans Trias i Pujol Hospital","companyId":"germans-trias-i-pujol-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that works by inhibiting the replication of HIV. Used for Treatment of HIV-1 infection in combination with other antiretroviral agents.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}